7.56
-0.14(-1.82%)
Currency In USD
| Previous Close | 7.7 |
| Open | 7.65 |
| Day High | 7.71 |
| Day Low | 7.46 |
| 52-Week High | 12.55 |
| 52-Week Low | 2.12 |
| Volume | 18,841 |
| Average Volume | 24,775 |
| Market Cap | 14.21M |
| PE | 0.4 |
| EPS | 18.83 |
| Moving Average 50 Days | 6.36 |
| Moving Average 200 Days | 4.84 |
| Change | -0.14 |
If you invested $1000 in Neuphoria Therapeutics Inc. (NEUP) since IPO date, it would be worth $42.77 as of July 16, 2025 at a share price of $7.56. Whereas If you bought $1000 worth of Neuphoria Therapeutics Inc. (NEUP) shares 3 years ago, it would be worth $86.01 as of July 16, 2025 at a share price of $7.56.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting
GlobeNewswire Inc.
May 27, 2025 8:10 PM GMT
BURLINGTON, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced an
Neuphoria Provides First Quarter 2025 Business Updates
GlobeNewswire Inc.
May 20, 2025 8:22 PM GMT
Cash runway into Q3 2026AFFIRM-1 Phase 3 clinical trial of BNC-210 in social anxiety disorder on track for topline readout in Q3 2025α7 nicotinic acetylcholine receptor PAM MK-1167 partnered with Merck and in Phase 2 clinical trial in Alzheimer’s BUR
Neuphoria Provides a Review of 2024 and Highlights 2025 Plans
GlobeNewswire Inc.
Apr 15, 2025 12:00 PM GMT
Initiation by Merck of a Phase 2 trial in Alzheimer’s disease with partnered α7 nicotinic acetylcholine receptor PAM MK-1167 highlights company’s pipeline diversification beyond BNC210US $15M milestone payment from Merck extends company’s cash runway